

Supplementary Table 1.

Summary of clinical characteristics of the 6 colorectal carcinoma (CRC) patients.

#	sex	age (years)	Site primary	Diagnosis of primary tumor = Dukes' stage (T stage, N stage (no. Positive Lnn/no. Examined Lnn), M stage, grade)*	Diameter of primary lesion (cm)	KRAS (primary tumor)	Interval between diagnosis of primary and first metastasis (months)	Sites of metastases	Largest diameter of metastasis (cm)	Interval between diagnosis of primary and blood collection (months)	Last therapy	Interval between blood collection and last therapy (days)	Dukes' stage**	CEA** (ref.:0-5)	CA-19-9** (ref.:0-37)
6	M	60	cecum	D (pT3 N1(1/6), M1, G3)	NA	G12V	0	Liver, abdominal lymphnodes, peritoneal carcinomatosis, bone, brain	6	8	6 cycles Oxaliplatin	48	D	4315	37044 8.00
9	M	70	rectum	D (only biopsy, therefore no data about T, N, G stage available), M1	NA	WT	0	Liver, lymphnodes, peritoneal carcinomatosis, bone	1.5	1	Surgery, no chemotherapy	34	D	39.4	2312. 00
18	M	54	recto-sigmoideum	D (only biopsy, therefore no data about T, N, G stage available), M1	NA	WT	0	Liver	5.9	1	∅	0	D	856.6	33.50
22	M	62	flexura coli sinistra	D (pT3 N2 (7/13) M1, G2)	0.3	WT	0	Liver, peritoneal carcinomatosis, adrenal gland	14.5	2	Surgery, no chemotherapy	2	D	1.6	<2
26	F	70	colon transversum	C (pT3 N1 (2/40)M0, G2)	2.3	WT	31	Liver, bone, spleen	3.5	34	12 cycles CPT11/ Erbitux	34	D	95.4	64.70
38	M	63	colon ascendens	B (pT3, N0 (0/28), M0, G2)	5	G12D	44	Liver, lung, bone, lymph nodes	9	45	Surgery, no chemotherapy	0	D	2.6	19.20

*: at time of diagnosis; **: at time of blood collection

M: male

F: female

NA: not available

WT: wild type

y: years m: months d: days

ND: not done